Clinical Trials
102 trialsNCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT01676818 2025-11-06
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
University of Southern California
Phase 2 Completed
NCT03264547 2025-09-29
EMERALD
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06533722 2025-06-10
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02061085 2025-06-08
MERIBEL
MedSIR
Phase 2 Completed
NCT03222856 2025-06-05
KELLY
MedSIR
Phase 2 Completed
NCT01827787 2024-11-06
Eribulin in HER2 Negative Metastatic BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT03840772 2024-09-20
ERASING
Italian Sarcoma Group
Phase 2 Completed
NCT04464174 2024-07-26
PATHFINDER
MedSIR
Phase 2 Completed
NCT02035813 2024-06-04
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University of Ulm
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02338037 2024-03-19
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Phase EARLY_PHASE1 Completed
NCT03051659 2024-03-06
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03262935 2023-10-19
TULIP
Byondis B.V.
Phase 3 Completed
NCT01463891 2023-07-24
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Eisai Inc.
Completed
NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
NCT01126736 2023-06-22
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
Phase 1/2 Completed
NCT01268150 2023-06-22
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01269346 2023-06-22
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01327885 2023-06-22
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Eisai Inc.
Phase 3 Completed
NCT01439282 2023-06-22
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01454934 2023-06-22
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT01795586 2022-10-31
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03441360 2022-10-05
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eisai Inc.
Phase 2 Completed
NCT03027245 2022-07-13
IRENE
Eisai Inc.
Completed
NCT02120469 2022-07-05
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03810976 2022-06-16
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed
NCT02513472 2022-05-05
ENHANCE-1
Eisai Inc.
Phase 1/2 Completed
NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT02555657 2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT01705691 2021-10-06
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02551263 2021-06-11
E-SPEC
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Completed
NCT02864030 2021-03-04
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase 4 Completed
NCT01554371 2021-02-03
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Completed
NCT01323530 2021-01-11
A Confirmation Study of Eribulin in Combination With Capecitabine
Eisai Inc.
Phase 1/2 Completed
NCT03430518 2020-08-05
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02581839 2020-07-30
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01908101 2020-07-23
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
University of Washington
Phase 2 Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed